PMV Pharmaceuticals surges on positive cancer therapy trial data

Pmv Pharmaceuticals

10/09/2025 12:44

** Shares of PMV Pharmaceuticals PMVP.O rise 30.6% to $2.08 premarket

** Experimental therapy rezatapopt showed tumor reduction in patients with advanced solid tumors with TP53 gene mutation in mid-stage study - co

** Interim data shows 33% overall response rate, median response duration of 6.2 months in advanced solid tumor patients

** The therapy showed responses in eight different tumor types, including lung, breast, and colorectal cancers

** PMVP plans new drug application for refractory ovarian cancer treatment in Q1 2027

** As of last close, stock up 6% YTD

 (Reporting by Siddhi Mahatole)

 ((siddhi.mahatole@thomsonreuters.com))